samedan logo
 
 
 
spacer
home > pmps > autumn 2008 > mes gets you to market quicker
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

MES Gets You to Market Quicker

Probably the biggest single driver for any manufacturer in the pharmaceutical industry has to be the time it takes to get a potential product through the research and development phases and out to market.

With R&D costs to bring a new drug to release approximated at $1 million a day, only when a product is in daily use does the huge investment undertaken by drug companies seeking the next blockbuster product begin to pay back.

There are plenty of examples, across many industries, of companies being late to market with a product, only to find further down the line that competitors’ products have subsequently appeared, with a resulting substantial hit in potential operating profits. Once a company is in the process of research...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mark Perry has held a number of senior positions, including Sales Director for ABB Process Instrumentation & Micro Control Systems and General Manager for Rockwell Automation EMEA Asset Management. He joined Siemens in 2003 as General Sales Manager for the Process Instrumentation Group before moving into the automation and drives process sector, heading up teams focusing on the chemical/pharmaceutical, food and beverage and oil and gas sectors. In 2007, Mark took up the position as Business Manager for the Siemens UK MES group, with responsibility for, among others, the pharmaceutical industry.
spacer
Mark Perry
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

New IATA Guidance Prepares for Global Vaccine Distribution

The International Air Transport Association (IATA) released guidance to ensure that the air cargo industry is ready to support the large-scale handling, transport and distribution of a COVID-19 vaccine. IATA’s Guidance for Vaccine and Pharmaceutical Logistics and Distribution provides recommendations for governments and the logistics supply chain in preparation for what will be the largest and most complex global logistics operation ever undertaken.
More info >>

White Papers

Advantages of Quantitative NMR for the Determination of Relative Response Factors

Novatia, LLC

Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement